Cell & Gene Therapies

Test may determine if immunogloubin can help treat autism

19-Sep-2018 By Maggie Lynch

A study demonstrated that IV immunogloubin may be able to help treat a subset of individuals with autism spectrum disorder.

Oncology vaccine ensured 100% survival rate in lab studies

18-Sep-2018 By Maggie Lynch

Scientists demonstrated that an adjuvant to an immunotherapy vaccine resulted in a 100% survival rate in mice with aggressive melanoma.

Thermo Fisher expands bioprocessing with BD acquisition

14-Sep-2018 By Ben Hargreaves

Thermo Fisher Scientific announced the acquisition of BD’s Advanced Bioprocessing unit, which will join its Life Sciences Solution business.

NORDIC LIFE SCIENCE DAYS

Missed #NSLDays in Sweden? Live dispatches from Stockholm

13-Sep-2018 By Flora Southey

As Nordic Life Science Days draws to a close for 2018, so too do the conference ‘super sessions’, covering patient engagement, precision medicine, drug delivery and immune-oncology.

Biopharma-Reporter is on the ground, bringing you the...

Morphogenesis initiates first in-human clinical trial after working with companion animals

12-Sep-2018 By Maggie Lynch

Morphogenesis launched its first in-human melanoma clinical study with Moffitt Cancer Center, as part of Moffitt’s Cutaneous Oncology Program.

Researcher develops ‘100x more effective’ solid tumor antibody therapy

07-Sep-2018 By Maggie Lynch

A researcher at UVA medical school has developed a ‘two-headed’ antibody approach to treat ovarian cancer and solid tumors.

CAR-T for kids: Kymriah enters under-25s market in UK

07-Sep-2018 By Flora Southey

The NHS has signed a commercial deal with Novartis, which will see ‘game changer’ therapy Kymriah supplied to children and young people in the UK.

Australian government awards funding to Indee Labs for microfluidic chip development

04-Sep-2018 By Maggie Lynch

NSW Medical Device Fund awarded Indee Labs funding for the company’s preclinical trial with their microfluidic chip alongside University of Sydney.

Novartis further invests in cell and gene therapy manufacture, after Kymriah approval

29-Aug-2018 By Ben Hargreaves

Novartis plans to step up its capabilities of manufacturing cell and gene therapies with a new facility to be built in Stein, Switzerland.

Bluebird cell therapy research to be advanced in AI collaboration

29-Aug-2018 By Maggie Lynch

Bluebird bio and Gritstone Oncology have collaborated to research, develop and commercialize cancer treatments using cell therapy with an AI platform.

CAR-T comes to Europe: Novartis and Gilead receive EU approvals

28-Aug-2018 By Ben Hargreaves

In a landmark decision, the European Commission has approved both Novartis’ Kymriah and Gilead’s Yescarta for the treatment of patients within the EU.

Astellas prioritises ophthalmology with gene therapy acquisition

21-Aug-2018 By Ben Hargreaves

Astellas has announced that it will acquire Quethera and its gene therapy programmes for the treatment of glaucoma.

Clinical trial boom boosts Cryoport revenues 59% in Q2 2018

21-Aug-2018 By Melissa Fassbender

Cryoport is supporting a record number of clinical trials driven by rapid growth in regenerative medicine – a space that will continue to grow and outpace the pharmaceutical industry, says CCO.